XML 75 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 176,319 $ 256,577 $ 212,958
License Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 14,323 177,086 22,269
Development Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 80,592 114,115 125,913
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 14,323 11,935 14,323
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 0 117,470 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 1,220 1,222 2,400
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 17,954 28,172 18,503
AstraZeneca Agreements [Member] | China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue (90) 90 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 0 47,681 7,946
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 61,508 $ 84,629 $ 104,970